Magnetic Group Signaling (MGS®) Technology

Magnetic Group Signaling (MGS®) standardizes NMR systems and sample processing to ensure reproducible results on different NMR instruments.

Learn more

One Sample -

All Answers

Advanced. Automated. Affordable. Mastering Metabolic Networks for Real-Time Precision Medicine.

Learn more

AXINON® System

AXINON® is the first modular software-based system providing hardware, operating system, MGS® processor and individual test applications.

Learn more

Cardiovascular Diseases. |CVD Risk Assessment.


Cardiovascular disease (CVD) is the number one cause of death wordwide1. 
The cause of CVD is atherosclerosis. Cardiovascular risk does not correlate with clinical symptoms until considerable atherosclerotic* disease progression.  Consequently, early accurate risk determination is part of an established clinical strategy of primary prevention. A number of guidelines have been established for the prevention, diagnosis, evaluation and management of CVD. The goal being the reduction of cardiovascular (CV) events such as acute heart attack (myocardial infarction, MI) and stroke. CV risk determination is therefore a key aspect of clinical care for all individuals between the age of 40-79.

Clinical CV risk factors include hypertension, diabetes mellitus, chronic kidney disease, obesity, cigarette smoking and family history. The most important biomarkers for CV risk determination are lipids including total cholesterol, triglycerides, LDL and HDL cholesterol. Early epidemiological studies associated both total cholesterol and LDL cholesterol to CV risk. Current studies have shown that there is discordance in quite a number of individuals based on the standard lipid profile. Thus, the determination of lipoprotein particle (LDL-P) numbers offers a more accurate risk assessment especially in those individuals with other comorbid conditions. A simple determination of total cholesterol with its subgroups HDL and LDL is thus no longer sufficient. As a consequence it is recommended to consult further parameters providing data beyond the conventional lipid panel.

<i>AXINON<sup>&reg;</sup> lipoFIT<sup>&reg;</sup>-S100</i>. |Innovative Lipoprotein Analysis.

Advanced. Automated. Affordable.

numares offers an on-site technology for the assessment of cardiovascular risk, i.e. an in-depth lipoprotein analysis.

Beyond the standard lipid panel, the AXINON® System provides a more detailed and standardized analysis of the lipoprotein subclasses, via Magnetic Group Signaling (MGS®) technology.

numares AXINON® lipoFIT®-S100 system** measures concentration, size and distribution of lipoprotein particles (which carry cholesterol)  and determines the respective quantity of the key compounds triglycerides, cholesterol and phospholipids.

More information on the AXINON® System:

Go to FAQs

<i>AXINON<sup>&reg;</sup> lipoFIT<sup>&reg;</sup>-S100</i>. |Lipoprotein Parameters.

Standard
lipid panel

Particle
concentrations

Particle
sizes

Metabolites

Total cholesterol
LDL cholesterol
HDL cholesterol
Triglycerides
LVLDL-p
LDL-p
SLDL-p
HDL-p
LHDL-p
VLDL-s
LDL-s
HDL-s 
Alanine
Valine
Leucine
Isoleucine 

 

More information on the AXINON® System:

Go to FAQs

Technology. |The<i> AXINON<sup>&reg;</sup> System</i>.

Easy. Fast. Efficient.

The AXINON® System enables comprehensive lipoprotein analysis and is suited for solid high-throughput operation with minimal hands-on time.

The combination of MGS® and the AXINON® System allows for spectral analysis with highly-reproducible results. The system is easy to use requiring minimal operator interaction. The system is fast and efficient with automation capabilities allowing short hands-on-time and high walk-away capability.

To date, more than 1.5 million tests have been performed worldwide using numares’ technology.

Go to Technology


1. Minino AM, Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2008. [Accessed September 12, 2012];Natl Vital Stat Rep. 2011 59:1–126. www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_10.pdf. [PubMed]

** For Research Use only in the United States. numares’ products are not yet available for sale within the United States; they have not yet been approved or cleared by the U.S. Food and Drug Administration.